{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-053086","form_type":"8-K","ticker":"GYRE","cik":"0001124105","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.287244+00:00","generated_at":"2026-06-08T03:11:49.202435+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"GNI Group, Gyre's controlling shareholder, reports 9M 2023 revenue ¥20.5B (+61%), net profit ¥2.2B (+106%)","bullets":["9M 2023 revenue of ¥20,547.9M, up 61% from ¥12,761.0M in prior year.","Net profit attributable to parent ¥2,213.3M vs ¥1,076.1M, more than doubled.","Operating cash flow ¥4,443.0M, turning from negative ¥162.9M in prior year.","Total assets ¥48,468.0M, up 33% from ¥36,456.9M at prior year-end.","Basic EPS ¥46.61 (9M) vs ¥22.67; diluted EPS ¥46.13 vs ¥22.46."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-053086","json":"https://secwatch.observer/filing/0001140361-23-053086.json","markdown":"https://secwatch.observer/filing/0001140361-23-053086.md","text":"https://secwatch.observer/filing/0001140361-23-053086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123053086/0001140361-23-053086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123053086/ny20009756x17_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:11:49.202435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}